21
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Insulin detemir: a better basal insulin for the management of diabetes?

Pages 15-23 | Published online: 10 Jan 2014
 

Abstract

The prevalence of diabetes mellitus continues to grow. The current number of people in the USA diagnosed with diabetes has reached 17.5 million and, in 2007, the cost of the disease reached US$174 billion. The common feature of diabetes is the relative lack of insulin. This defect appears to worsen over the lifetime of the individual, necessitating the introduction of insulin therapy in most affected individuals. Of the various choices, basal insulin is commonly initiated as the first insulin. There are three choices for basal insulin; two insulin analogs (insulin glargine and insulin detemir) and neutral protamine Hagedorn (NPH) insulin. Although NPH is inexpensive, its use is fraught with unpredictability and, in some cases, an insufficient duration of action. Both insulin analogs have an advantage over NPH by possessing a longer duration and fewer complications of hypoglycemia. Compared with insulin glargine, detemir may have a greater advantage owing to lower within-patient variability of action, incidence of hypoglycemia and weight gain.

Acknowledgements

The author would like to acknowledge the assistance of Gary Wolfe.

Financial & competing interests disclosure

A King has been a speaker and received research funding from Novo-Nordisk, Lilly and Sanofi-Aventis. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.